Literature DB >> 7084284

The pharmacokinetics of benoxaprofen in elderly subjects.

R C Hamdy, B Murnane, N Perera, K Woodcock, I M Koch.   

Abstract

Benoxaprofen plasma profiles were obtained in two groups of elderly female patients. A single dose of benoxaprofen, either 600 mg or 300 mg, was given and blood levels were measured daily to 120 hours. Mean peak plasma levels were reached at five hours following the 600-mg dose and at seven hours after the 300-mg dose. Elimination half-lives calculated from levels during 36-120 hours resulted in means of 111 hours and 86.4 hours for the 600-mg and 300-mg doses respectively. (Normal subjects, 30 to 35 hours.) Because of these extended half-lives, a further study was conducted following a single 600-mg dose to four more patients. Blood vessels were measured up to 504 hours (21 days). This resulted in a means half-life of 147.9 hours calculated from levels during 168-504 hours. Although serum creatinine levels ere not generally above the normal for this age group, calculated creatinine clearances were considerably reduced. It is concluded that the high plasma benoxaprofen levels achieved, combined with the slow clearance rates and long half-lives, indicate that it may be possible to work is needed to determine whether this prolonged half-life is matched by an equally prolonged therapeutic effect.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7084284

Source DB:  PubMed          Journal:  Eur J Rheumatol Inflamm        ISSN: 0140-1610


  22 in total

Review 1.  Choosing the right nonsteroidal anti-inflammatory drug for the right patient: a pharmacokinetic approach.

Authors:  N M Davies; N M Skjodt
Journal:  Clin Pharmacokinet       Date:  2000-05       Impact factor: 6.447

Review 2.  Idiosyncratic drug reactions: a mechanistic evaluation of risk factors.

Authors:  B K Park; M Pirmohamed; N R Kitteringham
Journal:  Br J Clin Pharmacol       Date:  1992-11       Impact factor: 4.335

Review 3.  Hepatic drug metabolism and aging.

Authors:  C Durnas; C M Loi; B J Cusack
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 4.  Drug development and use in the elderly: search for the right dose and dosing regimen (Parts I and II).

Authors:  Rashmi R Shah
Journal:  Br J Clin Pharmacol       Date:  2004-11       Impact factor: 4.335

5.  Pharmacokinetics of the anti-inflammatory drug ximoprofen in healthy young and elderly subjects: comparison with elderly rheumatic patients.

Authors:  I W Taylor; L F Chasseaud; T Taylor; I James; G Dorf; A Darragh
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

6.  The pharmacokinetics of sustained release tiaprofenic acid in elderly arthritic patients.

Authors:  G A Hosie; J Hosie
Journal:  Br J Clin Pharmacol       Date:  1987-07       Impact factor: 4.335

7.  A comparison of isoxicam pharmacokinetics in young and elderly subjects.

Authors:  C F George; A G Renwick; A S Darragh; J Hosie; D Blake; W van Marle; G J Frank
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

Review 8.  Drug-induced liver injury in the elderly.

Authors:  Jonathan G Stine; Praveen Sateesh; James H Lewis
Journal:  Curr Gastroenterol Rep       Date:  2013-01

9.  Piroxicam and naproxen plasma concentrations in patients with osteoarthritis: relation to age, sex, efficacy and adverse events.

Authors:  H E Rugstad; O Hundal; I Holme; O B Herland; G Husby; K E Giercksky
Journal:  Clin Rheumatol       Date:  1986-09       Impact factor: 2.980

Review 10.  Pharmacokinetic optimisation of the treatment of osteoarthritis.

Authors:  K J Skeith; D R Brocks
Journal:  Clin Pharmacokinet       Date:  1994-03       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.